2) This 3⃣ rd installment addresses key pertinent data from #ESGO2023, held in #Istanbul last month.#FOAMed #onctwitter #ecsm #gyncancersm
— @onc_ce (@onc_ce) November 14, 2023
Follow us for regular #accredited updates across #oncology, all delivered right here on X ! pic.twitter.com/Rl9t8Jy4YP
4a) @ESGO_society #ESGO23 lived up to its billing as the European Voice of #Gynecological #Oncology. The well-attended meeting hosted the presentation of cutting-edge data across multiple topics, including advanced #endometrial #cancer!
— @onc_ce (@onc_ce) November 14, 2023
5) #EndometrialCancer is the 6th most common cancer in 🚺worldwide. Incidence & mortality are both ⬆️! Localized dz often curable but poor outcomes in advanced dz so more treatment options needed. pic.twitter.com/VWkL98vpXh
— @onc_ce (@onc_ce) November 14, 2023
6b) As a reminder, #RUBY (ENGOT-EN6-NSGO/GOG-3031) is an ongoing Ph 3 trial in primary advanced (St 3-4) & first recurrent #EC w/ random assignment 1:1 to #dostarlimab (500 mg), or placebo, plus #carboplatin & #paclitaxel . . .
— @onc_ce (@onc_ce) November 14, 2023
6d) … so combined with #immunotherapy may have synergistic effects in the tumor microenvironment. Proof of concept already published in @nejm: https://t.co/AN8RNIzoaT pic.twitter.com/dAm1sdmthA
— @onc_ce (@onc_ce) November 14, 2023
7b) Data on #QTWIST in #RUBY was presented for 3 cohorts: overall safety population, the mismatch repair-deficient/microsatellite instability-high (#dMMR/#MSI_H) population, & the MMR-proficient/microsatellite-stable (#pMMR/#MSS) cohort.
— @onc_ce (@onc_ce) November 14, 2023
9a) We also had an update on detailed safety data from #RUBY. This was presented by #AnnikaAuranen from @UniTurku. pic.twitter.com/cAC4r9eAmN
— @onc_ce (@onc_ce) November 14, 2023
9c) In the Ph3 #RUBY trial of dostarlimab/placebo + #carboplatin/#paclitaxel at this data cut, 5 ☠️ were reported, but only two were deemed related to #dostarlimab. The most common #TEAEs were #fatigue #alopecia & #nausea & more common Gr3+ AEs were #anemia & #neutropenia: pic.twitter.com/k8DFjbmQpw
— @onc_ce (@onc_ce) November 14, 2023
10b) DB-1303 = humanized IgG1 #Mab (#trastuzumab #biosimilar targeting #HER2 [BAT0606]), a payload of #DNA #topisomerase1 inhibitor (#P1003), & an enzymatically cleavable tetrapeptide-#maleimide linker (#L101P1003).
— @onc_ce (@onc_ce) November 14, 2023
11a) At #ESGO2023, data were presented on 32 #ECpatients; #histology included #serous papillary #carcinoma, #adenocarcinoma, & #carcinosarcoma. The latter 2 are more likely to have PD-L1 expression.
— @onc_ce (@onc_ce) November 14, 2023
11c) Responses were seen in 10/17 evaluable patients, 50% at 7mg/kg (n=4) and 61% at 8mg/kg (n=13). Disease control rate was 94.1%.
— @onc_ce (@onc_ce) November 14, 2023
🦺 Most common #TEAEs of any grade were #vomiting #fatigue #nausea, and most common Gr 3 & above TEAEs were #syncope #anemia #hypokalemia. pic.twitter.com/VoLN4VWgKi
12b) Wrapping up #immunotherapies for #EC, #ESGO2023 new data:
— @onc_ce (@onc_ce) November 14, 2023
👉new data on #DB_1303, novel #ADC targeting #HER2 #EC:
1⃣ only (ongoing) Ph 1/2 trial, but appears to have reasonable safety profile
2⃣ shows promising anti-#tumor activity
14a) Xhindoli reviewed experience from #tertiary referral center European Institute of Oncology in #Milan. They prospectively characterized recurrence-free survival among 4 molecular classes of all cases St 1-3 #EC since April 2019:
— @onc_ce (@onc_ce) November 14, 2023
14c) Looking at these markers, clinical characteristics, and survival, their data supported previous work that #POLEmut may have a protective role in #EC & that #p53abn positivity actually portends poorer outcomes. In this study, the overall recurrence rate in 239 pts was 12.1%: pic.twitter.com/8R3grWie33
— @onc_ce (@onc_ce) November 14, 2023
15b) She looked at #PD1, #PDL1, and #IFNγ. Interestingly, PD-1 #mRNA levels were ~7x higher in #EC tissue than in controls. PD-L1 immune checkpoint expression in EC tissue was 3x greater, and IFNγ expression was 5x greater than controls, all P < 0.001.
— @onc_ce (@onc_ce) November 14, 2023
She concluded:
15d) She summarized: #immune #checkpoint expression in #EC often correlates with clinical outcomes, and levels of expression should guide treatment strategies pic.twitter.com/Tgr0uthFGz
— @onc_ce (@onc_ce) November 14, 2023
16b) This trial is recruiting pts w/ advanced/recurrent #EC who have received #chemo up to 6 cycles ➡️ partial/complete response & then are randomized to either 1 of 2 doses of #navtemadlin in 4-wk cycles vs observation.
— @onc_ce (@onc_ce) November 14, 2023
Ph2 goal = identify optimal Ph3 dose. Ph3 1º endpoint = PFS pic.twitter.com/AWmy0wrVU5
16d) The study arms being evaluated in this maintenance therapy trial (ENGOT-En21 and GOG-3089) are
— @onc_ce (@onc_ce) November 14, 2023
1⃣ 180mg #navtemadlin per day
2⃣ 240 mg navtemadlin per day
3⃣ observation
Watch this one! pic.twitter.com/4YpO9WBJ61
17b) #Selinexor is a 1st-in-class, oral Selective Inhibitor of Nuclear Export (#SINE) compound. It binds with & inhibits the nuclear export protein #XPO1, ➡️accumulation of tumor suppressor proteins in the cell nucleus.
— @onc_ce (@onc_ce) November 14, 2023
(Figure from 🔓 https://t.co/kj6PUOs6CC) pic.twitter.com/ASJz6ZJpPU
18a) At #ESGO2023, J PérezFidalgo presented this analysis of long-term f/u of #selinexor maintenance in pts with #TP53wt advanced (St 4) or recurrent #EC. After response to #chemo pts are randomized to maintenance selinexor or #placebo. pic.twitter.com/JjTGKGEvDj
— @onc_ce (@onc_ce) November 14, 2023
18c) Most common #TEAEs of any grade were #nausea #vomiting #diarrhea, & most common Grade 3+ were #neutropenia #nausea & #thrombocytopenia.
— @onc_ce (@onc_ce) November 14, 2023
🔭This work has now advanced to globally enrolling Ph3 ENGOT-EN20, enrolling only pts with #TP53wt #EC after response to initial chemo
19b) It’s d . . . see post 14c above. Now, which of the following immune checkpoint molecular expression profiles has been shown to be predictive for #RFS?
— @onc_ce (@onc_ce) November 14, 2023
20) And so you are caught up on the latest data from #ESGO2023 on advanced & recurrent #endometrial #cancer #EC. Thank you to @DrMeredithGT for leading us through all this 🆕data! Now you can claim 0.75hr 🆓 CE/#CME by simply clicking on https://t.co/dxtP6Xdl8q.
— @onc_ce (@onc_ce) November 14, 2023
Follow us!